Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non-Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,652
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
stocks
Impact of ANZ’s huge fine
stocks
Acquisition a sign of weakness for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,151.20 | 1.30 | -0.01% |
CAC 40 | 7,886.51 | 10.42 | -0.13% |
DAX 40 | 23,626.37 | 122.49 | -0.52% |
Dow JONES (US) | 45,883.45 | 49.23 | 0.11% |
FTSE 100 | 9,252.88 | 24.15 | -0.26% |
HKSE | 26,438.51 | 8.05 | -0.03% |
NASDAQ | 22,348.75 | 207.64 | 0.94% |
Nikkei 225 | 44,902.27 | 134.15 | 0.30% |
NZX 50 Index | 13,234.89 | 26.58 | 0.20% |
S&P 500 | 6,615.28 | 30.99 | 0.47% |
S&P/ASX 200 | 8,877.70 | 3.00 | -0.03% |
SSE Composite Index | 3,861.86 | 1.36 | 0.04% |